1. News

CENTOGENE announces the Appointment of a New Supervisory Board Member

Rostock, Germany, May 4, 2018 – CENTOGENE, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, today announced the appointment of Berndt Modig as a new member to its Supervisory Board. Berndt has an extensive experience of more than 25 years in biotech companies. He currently serves as a director and Audit Committee chair of Axovant Sciences Ltd., member of the Audit Committee of Affimed N.V. and vice chairman of the Supervisory Board and chair of the Audit Committee of Kiadis Pharma N.V., all publicly held pharmaceutical companies. In addition to that, he is the Chief Executive Officer and co-founder of Pharvaris BV. Previously, Berndt was Chief Financial Officer of Prosensa Holding N.V., a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases, from March 2010 through its IPO on the NASDAQ in 2013 until its acquisition by BioMarin Pharmaceutical Inc. in 2015. Prior to Prosensa, Berndt was Chief Financial Officer at Jerini AG through its IPO on the Frankfurt exchange in 2005 and sale to Shire Plc in 2008. Berndt also held in the past a variety of senior management positions at Surplex AG, Hayward Industrial Products, Agra Industria and Price Waterhouse LLP.

Prof. Arndt Rolfs, CEO and founder of CENTOGENE stated: “We are delighted to have Berndt Modig as new member of the Supervisory Board of CENTOGENE.  With his impressive track record in senior leadership roles, Berndt will enlarge The Board´s already wide breath of expertise and will provide the strategic guidance to further speed up the worldwide development of CENTOGENE, especially in the global financial world.”

“I am very excited to join the Supervisory Board at CENTOGENE and I am looking forward to leverage my experience in supporting the management team to achieve its ambitious goals of global growth. Especially the clear focusing of CENTOGENE on further pharma collaborations based on the biomarker development and the patient centric models make the positioning of the company so attractive” said Berndt Modig. 

Subscribe to our Newsletter